Information Provided By: 
Fly News Breaks for December 10, 2017
ATRC
Dec 10, 2017 | 18:16 EDT
Piper Jaffray analyst Matt O'Brien notes that he hosted investor meeting with AtriCure's CFO Andy Wade. Looking longer-term, the analyst believes the results of the Converge trial and a sub-x Clip might result in accelerating growth starting in 2020, which he believes would push shares much higher. Consequently, O'Brien encourages investors to start or build positions in this "compelling franchise." He reiterates an Overweight rating and $24 price target on the shares.
News For ATRC From the Last 2 Days
There are no results for your query ATRC
